Compare
EBR Systems, Inc. vs Vycor Medical Inc vs Femasys Inc vs RenovoRx, Inc.
| Latest fiscal year | EBR Systems, Inc. NONE. | Vycor Medical Inc VYCO | Femasys Inc FEMY | RenovoRx, Inc. RNXT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.62M | $1.86M | $2.29M | $1.12M |
| Revenue growth (YoY) | n/a | +17.2% | +40.8% | n/m |
| Gross margin | 30.3% | 83.8% | 62.0% (computed) | 70.9% |
| Operating margin | n/m | 1.8% | -767.0% | n/m |
| Net margin | n/m | -3.9% | -812.3% | -994.5% |
| Net income | -$48.76M | -$72.4K | -$18.63M | -$11.17M |
| EPS (Diluted) | -$0.12 | -$0.01 | -$0.47 | -$0.32 |
| Operating cash flow | -$53.19M | -$13.5K | -$18.69M | -$10.97M |
| Free cash flow | -$56.88M | -$18.7K | -$19.22M | -$10.97M |
| Cash & equivalents | $5.79M | $87.0K | $9.27M | $7.02M |
| Total assets | $97.23M | $830.4K | $20.72M | $8.10M |
| Total liabilities | $71.64M | $4.92M | $14.85M | $2.67M |
| Shareholders' equity | $25.59M | -$4.09M | $5.87M | $5.42M |
| Return on year-end equity | -190.6% | n/a | -317.4% | -206.0% |
| Shares outstanding | 450.26M | 33.37M | 59.60M | 36.61M |
Revenue, most recent five fiscal years
| Fiscal year | EBR Systems, Inc. | Vycor Medical Inc | Femasys Inc | RenovoRx, Inc. |
|---|---|---|---|---|
| Latest | $1.62M Ended 2025-12-31 | $1.86M Ended 2025-12-31 | $2.29M Ended 2025-12-31 | $1.12M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.59M Ended 2024-12-31 | $1.63M Ended 2024-12-31 | $43.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $1.46M Ended 2023-12-31 | $1.07M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $1.22M Ended 2022-12-31 | $1.21M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $1.39M Ended 2021-12-31 | $1.18M Ended 2021-12-31 | n/a |